Table 3.
Determinants of eGFR slope in study patients
| Characteristics | Univariate |
Multivariate (Stepwise) |
||
|---|---|---|---|---|
| Standardized Coefficient β | P | Standardized Coefficient β | P | |
| Male versus female | 0.158 | 0.057 | — | — |
| Smoking (ever versus never) | −0.105 | 0.212 | — | — |
| Diabetes mellitus | −0.224 | 0.007 | — | — |
| Hypertension | −0.252 | 0.019 | −0.193 | 0.011 |
| Coronary artery disease | 0.072 | 0.389 | — | — |
| Cerebrovascular disease | −0.070 | 0.402 | — | — |
| Heart rate (beat/min) | −0.252 | 0.002 | — | — |
| Body mass index (kg/m2) | 0.026 | 0.759 | — | — |
| Laboratory parameters | — | — | ||
| albumin (g/dl) | 0.142 | 0.100 | — | — |
| fasting glucose (log mg/dl) | −0.117 | 0.160 | — | — |
| triglyceride (log mg/dl) | −0.208 | 0.012 | — | — |
| HDL-cholesterol (mg/dl) | 0.116 | 0.165 | — | — |
| LDL-cholesterol (mg/dl) | 0.164 | 0.051 | — | — |
| hematocrit (%) | 0.383 | <0.001 | — | — |
| baseline eGFR (ml/min per 1.73 m2) | 0.448 | <0.001 | 0.408 | <0.001 |
| calcium (mg/dl) | 0.207 | 0.013 | — | — |
| phosphate (mg/dl) | −0.291 | <0.001 | — | — |
| uric acid (mg/dl) | −0.112 | 0.180 | — | — |
| PTH (log pg/ml) | −0.347 | <0.001 | — | — |
| Albuminuria | −0.293 | <0.001 | — | — |
| baPWVa (cm/s) | −0.278 | 0.001 | −0.165 | 0.033 |
| Medications | ||||
| aspirin use (%) | −0.048 | 0.567 | — | — |
| ACEI and/or ARB use (%) | 0.100 | 0.233 | — | — |
| β-blocker use (%) | −0.077 | 0.422 | — | — |
| calcium channel blocker use (%) | −0.084 | 0.318 | — | — |
| diuretic use (%) | 0.029 | 0.729 | — | — |
| statin use (%) | −0.056 | 0.505 | — | — |
| ESA use (%) | −0.037 | 0.659 | — | — |
Adjusted R2 = 0.270. Values expressed as standardized coefficient β.
a
Data were adjusted for mean arterial pressure.